In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Before starting elacestrant, discuss any questions or concerns with your medical···【more】
Release date:2026-02-02Recommended:344
Take elacestrant daily and always follow the guidance of your medical team stric···【more】
Release date:2026-02-02Recommended:315
Elacestrant is indicated for the treatment of postmenopausal women or adult men ···【more】
Release date:2026-02-02Recommended:315
Anagrelide is indicated to reduce the risk of blood clots in patients with throm···【more】
Release date:2026-01-30Recommended:294
Special caution is required when using anagrelide, as certain drugs may interact···【more】
Release date:2026-01-30Recommended:285
Anagrelide may cause a range of side effects during use.What side effects may An···【more】
Release date:2026-01-30Recommended:272
Anagrelide is used to reduce the platelet count in patients with myeloproliferat···【more】
Release date:2026-01-30Recommended:307
Revumenib (Revuforj) is an oral, first-in-class targeted Menin protein inhibitor···【more】
Release date:2026-01-29Recommended:366
Revumenib (trade name: Revuforj) is an oral, first-in-class targeted Menin inhib···【more】
Release date:2026-01-29Recommended:300
Revumenib (trade name: Revuforj) is an oral targeted drug of the Menin inhibitor···【more】
Release date:2026-01-29Recommended:408
Revuforj carries a risk of differentiation syndrome, and patients and their fami···【more】
Release date:2026-01-29Recommended:380
Rivimeinib is available in three tablet strengths: 25 mg, 110 mg, and 160 mg.Wha···【more】
Release date:2026-01-28Recommended:291